Canada’s regulatory approach to drugs for rare diseases: orphan drugs

Canada's regulatory approach: Drugs for rare diseases are authorized for sale in Canada under the Food and Drugs Act and Part C of the Food and Drug Regulations.

Data and Resources

Additional Info

Field Value
Source
Version
Author
Author Email
Maintainer
Maintainer Email
Data Level
Agreement Required
Purpose Constraints
Redistribution Allowed
AI Training Allowed
Data Steward
Title (French) Approche du Canada en matière de réglementation des médicaments utilisés pour soigner les maladies rares : les médicaments orphelins
Update Frequency as_needed
Geographic Scope []
Criticality Level []
Sensitivity Level unrestricted
Language
Contact Person
Contact Email
Data Dictionary
Open Canada Date Published 2022-04-01 00:00:00
Open Canada Date Modified
Open Canada Subject ["health_and_safety"]
Open Canada Keywords {"fr": ["Approche réglementaire du Canada", "médicaments contre les maladies rares", "médicaments orphelins"], "en": ["Canada’s regulatory approach", "drugs for rare-diseases", "orphan drugs"]}
Open Canada Collection publication
Principal Organization
Reference Data
Official Source